Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 50Recurrence 6Myelodysplastic Syndromes 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Leukemia, Myeloid 2Leukemia 2Hematologic Neoplasms 2Targeted Therapy 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Infections 1Disease 1Blast Crisis 1Advanced Solid Tumors 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × gilteritinib × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡